Objective: Based on positive safety and efficacy data, a quadrivalent Human PapillomaVirus
(HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 …

Aim Clinical trials have demonstrated the efficacy of the tetravalent human papillomavirus
(HPV) vaccination in the prevention of cervical cancer and genital warts associated with …

Addition of the HPV vaccine to available cytological screening has been proposed to
increase HPV-related cancer prevention. A comprehensive review on this combined strategy …

Background We assessed the cost-effectiveness of adding a quadrivalent (6/11/16/18)
human papillomavirus (HPV) vaccine to the current screening programme in the UK …

Background Infection with HPV 16 and 18, the major causative agents of cervical cancer,
can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines …

Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …

We evaluated the cost‐effectiveness of HPV16/18 vaccination for girls aged 12 years in The
Netherlands in addition to cervical cancer screening. For this purpose, we developed a …

BACKGROUND: The use of human papillomavirus (HPV) vaccines has been universally
approved for women from age 12 to 25 years, but those older than 16 years receive no …

Despite an effective screening programme, 600–700 women are still diagnosed with
cervical cancer in the Netherlands each year. In 2009 a prophylactic vaccine against HPV …

We studied the cost-effectiveness of cervical cancer prevention strategies in the Central and
Eastern Europe and Central Asia (CEECA) region. The cost-effectiveness of human …